NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Bandırma Onyedi Eylül University
Conditions: Respiratory Tract Diseases, Pediatric Disorders, Anxiety, Fear
Interventions: Virtual Reality Goggles (VR BOX), Interactive Distraction Cards (DistrACTION® Cards), Standard Clinical Care
Countries: Turkey (Türkiye)
This study aims to evaluate the effects of using virtual reality headsets and play cards during the administration of inhaler medication in pediatric patients. The primary goal is to determine how these distraction methods influence children's fear, anxiety levels, and physiological parameters (such as heart rate and oxygen saturation). The study population consists of pediatric patients aged between 4 and 6 years. Data collection for the targeted sample size of 150 children commenced in September, and the recruitment process is currently ongoing.Children receiving inhaler treatments often experience fear and anxiety, which can negatively affect their treatment compliance and vital signs. In this study, participants are divided into different groups to compare the effectiveness of virtual reality headsets and traditional play cards as distraction tools.
Sex: ALL
Age: 4 Years to 6 Years
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Inclusion Criteria: * Child being between the ages of 4 and 6 years. * Parents and children being completely voluntary to participate in the study. * Child having no visual, auditory, or cognitive communication barriers. * Child's cognitive level and motor development being appropriate for their age. * Child having no life-threatening acute or chronic systemic disease. * Child having no mental or neurological disability or condition. * Child and parent being fully open to effective communication and clinical cooperation. * Child having no medical condition that prevents inhaler mask or nebulizer application. Exclusion Criteria: * Child having any acute clinical condition that mechanically prevents inhaler treatment. * Child having a severe, life-threatening acute or chronic health problem at presentation. * Sudden development of severe clinical instability preventing completion of the trial.
- Balıkesir, Balıkesir, Turkey (Türkiye)